Auspherix: Meeting the urgent need for new antibiotics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Auspherix: Meeting the urgent need for new antibiotics
Released on: December 15, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria.
  • Summary
  • Participants
  • Company
Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the existing arsenal of antibacterial treatments.
Neil Miller, CEO
Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria. By developing a new class of antibiotics the Company will strengthen the existing arsenal of antibacterial treatments. Auspherix’ pre-clinical R&D programmes are based on its discovery of antibacterials with a unique profile. These proprietary compounds have demonstrated activity against a broad range of important multidrug resistant (MDR) Gram-negative and Gram-positive bacterial strains. The Company intends to develop and license these novel antibiotic drug candidate molecules to pharmaceutical companies with expertise in the anti-infective space.